iRegene Therapeutics
Cell Therapy Product Developer
2025Year12Month22Breaking News in the Biopharmaceutical Field——iRegeneNouvNeu001Injection successfully obtained in the United StatesFDAGranted Advanced Regenerative Medicine Therapy (RMAT) Recognition.
This milestone achievement has made the product the world's first to be approved in the field of neurological diseases.RMATTheiPSCChemically induced universal cell therapy product, setting a global first by simultaneously securingFDAFast Track Designation (FTD) andRMATDual RecognitioniPSCProduct records highlight the high recognition from international authoritative regulatory bodies of its clinical value and innovative strength.
Dual Recognition Behind: FDA’s Double Endorsement of Clinical Value
RMAT（Regenerative Medicine Advanced Therapy) is2016Year {21The Special Accelerated Approval Channel Established by the Century Cures Act Focuses on Regenerative Medicine Therapies with Significant Clinical Value, Aiming to Address Unmet Medical Needs and Facilitate the Rapid Market Entry of Innovative Therapies.
Products that receive this designation can enjoy benefits similar to those of Breakthrough Therapy (BTD) Similar multi-acceleration support, including withFDAEarlier and more frequent communication, rolling review eligibility, and potential accelerated approval and priority review pathways can significantly shorten the translation cycle from clinical to market.
And just2025Year8Month,NouvNeu001Successfully SecuredFDAFast Track Designation (FTD), adding another one within just four months.RMATRecognition, this“Dual Certification”This not only fully affirms the integrity of its clinical data and the rigor of the clinical trials but also confirms the breakthrough value of this product in the field of Parkinson's disease treatment.
FDAWill beNouvNeu001Providing customized clinical development guidance, covering key aspects such as trial design, selection of clinical endpoints, and accelerated approval pathways, to ensure the smooth global market entry of products.
Directly Addressing Treatment Pain Points: First-In-Class Technology Achieves Disease Reversal
As the world's second-largest neurodegenerative disease, the current treatment methods for Parkinson's disease are still limited to symptomatic treatment or complication management. These methods cannot fundamentally repair damaged dopaminergic neurons, let alone reverse the progression of the disease.
NouvNeu001The development precisely targets this clinical gap, offering patients the potential to alter disease progression through innovative cell replacement therapy.
This product is based on iRegene's proprietary intellectual property.“AI+Chemical Induction”Technical platform achieves the directional differentiation of high-purity specific dopaminergic neuron subtypes, while completing multiple functional modifications such as cell biochemistry during the induction process to meet clinical needs.
Different from traditional therapies,NouvNeu001By transplanting cells to fill the functional cell deficiency at the lesion site, repairing neural circuit damage caused by Parkinson's disease, and enabling patients to regain their dopamine self-secretion function, this approach truly has the potential to reverse the course of the disease, making it a world-first innovation.First-In-ClassTechnical Route.
Clinical Data Stuns: Efficacy and Safety Both Lead the Way
NouvNeu001The breakthrough value has been supported by solid clinical data. In the Phase I clinical trial for Parkinson's disease, the product utilized the world’s first single-needle-path stereotactic drug delivery method, which not only ensured maximum safety in the drug delivery process but also achieved long-term survival and integration of transplanted cells.
In terms of efficacy, it has demonstrated an internationally leading level: single-dose administration in subjects.12Months later, the motor function score (MDS-UPDRS III) InOFFAverage Improvement in Status30.6Points, with an improvement幅度达52.82%; InONAverage Improvement in Condition13.6Points, with an improvement幅度达54.67%, significantly superior to existing various treatment options. These statistically significant clinical results further solidify its core competitiveness in the global Parkinson's disease treatment market.
R&D Progress Continues to Lead: Global Multicenter Clinical Trials Steadily Advancing
Since the start of the research and development,NouvNeu001The progress has always maintained a globally leading position, forming a clinical development pattern that advances simultaneously in China and overseas:
- 2023Year8Month, obtained in ChinaNMPAApproval for the Treatment of Moderate to Severe Parkinson's DiseaseI/IIPhase Joint Clinical Trial;
- 2023Year12In the month, the National Geriatric Medical Center at Beijing Hospital, Ministry of Health, was officially launched.IPhase Clinical;
- 2024Year3Month, ObtainFDASpecial exemption, recognizing its breakthrough innovation platform and robust quality system;
- 2024Year6Month,FDAApprovalIND, Launch International MulticenterIPhase Clinical Trial;
- 2024Year11Month, completed in ChinaIPhase clinical trial enrollment;
- 2025Year4Month, Launch in ChinaIIPhase clinical trials, and advancing overseas multi-center in multiple countriesIPhase Clinical;
- 2025Year7Month,IIFirst Batch of Patients in Phase Clinical Trial Completed Dosing;
- 2025Year8Month, CaptureFDAFast Track Designation (FTD）；
- 2025Year12Month, AgainFDAAdvanced Regenerative Medicine Therapies (RMAT) Recognition.
This series of coherent regulatory breakthroughs and clinical progress is inseparable from the常态化, forward-looking regulatory coordination mechanism established by iRegene in the early stages of its research and development. Relying on solid non-clinical data and a comprehensive...CMCSystematically, the company continuously drives key R&D milestones to gain regulatory approval, laying a solid foundation for rapid product advancement.
Accelerating Benefits for Patients Worldwide: The Mission and Responsibility of Innovative Therapies
“ObtainRMATRecognition, isNouvNeu001An important regulatory milestone in the R&D process, fully demonstrating its clinical value and innovation.”Dr. Meng Cai, Chief Medical Officer of iRegene, stated,This recognition not only reflectsFDAThe recognition of the product's potential to address severe unmet medical needs provides a structured pathway for deeper and more efficient collaboration between the company and regulatory authorities.“We will make full use of this qualification to accelerate global multi-center clinical trials and strive to make this revolutionary therapy benefit patients worldwide as soon as possible.”
From China to the world, from preclinical research to dual major regulatory designations,NouvNeu001Every step of progress is driving a revolution in the field of Parkinson's disease treatment. As the world's firstFTDAndRMATDual CertificationiPSCThe product not only demonstrates the innovation of Chinese pharmaceutical companies in the field of cell therapy“From0To1”The breakthrough capability is more likely to bring hope of a cure to tens of millions of Parkinson's disease patients worldwide.
In the future, with the continuous advancement of global multi-center clinical trials, this breakthrough therapy will accelerate its path to market, bringing a new paradigm for the treatment of neurodegenerative diseases.
